| Trial ID # | NCT04625270: RAMP 201 |
| Phase | II |
| Drug Class | Signaling Pathway Inhibitors: RAS-RAF-MEK-ERK/RAF-MEK |
| Drug Name | Avutometinib |
| Alternate Drug Names | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 |
| Drugs in Trial | Avutometinib, Defactinib |
| Eligible Participant | Recurrent low grade serous ovarian cancer |
| Patients Enrolled | 62 patients; Avu: 33, median 3 prior therapies (1-10); Avu+Def: 31, median 4 prior therapies (1-11) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | Results from PART A: ORR: 45 (13PR, n=29) vs 10% (1CR, 2PR, n=30) KRAS MUT: Avu+Def (n=15) vs Avu (n=15): KRAS WT: Avu+Def (n=14) vs Avu (n=16): |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of avutometinib with defactinib yields encouraging response rates with a well tolerated safety profile in women with heavily pretreated recurrent LGSOC regardless of KRAS status and with prior MEK inhibitor treatment |
| Reference | Banerjee SN et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol 41, 2023 (suppl 16; abstr 5515) Banerjee SN et al. Poster Banerjee S et al. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG3052/RAMP 201 Part A. SGO (2024) |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.